Ginkgo Bioworks Holdings (DNA)

Ginkgo Bioworks Holdings, Inc. is a U.S.-based life sciences tools and services company listed on the NYSE under the ticker DNA. The company develops a cell engineering platform that supports research, development, and commercialization of engineered organisms and related products. Its operations are organized into Cell Engineering and Biosecurity segments. Within cell engineering, Ginkgo provides R&D solutions and a set of tools that include functional genomics, antibody developability, small molecule developability, artificial intelligence models, and reconfigurable automation cart systems. Through its biosecurity activities, it offers biomonitoring and bioinformatics support via Canopy and digital surveillance, analytics, and insights through Horizon. The company also works in genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection, and plant trait optimization, serving customers in pharmaceuticals, biotechnology, agriculture, industrial and environmental markets, food and nutrition, consumer and technology, and government and defense.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NYSE-DNA
$10.73
14.5% Upside
Fair
$7
-25.3% Downside
Overvalued
Fair
0.0%
November 16, 2026
1.3x
4.1x
631 M
616.9 M
42.9%
74.1%
-9.3
56.5%
Valuation • Fair Value

Ginkgo Bioworks Holdings (NYSE-DNA) Fair Value by Valuation Model

Review the available estimates for Ginkgo Bioworks Holdings (NYSE-DNA), including EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$10.73

Estimated upside of 14.5% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

EPV Fair Value

$8.20

Earnings power value estimate.

Comps Fair Value

$11.15

Comparable-company valuation reference.

Analyst Price Target

$7

Analysts imply downside of 25.3%.

How to read these valuation models

Use the 5 available valuation references for Ginkgo Bioworks Holdings (NYSE-DNA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Ginkgo Bioworks Holdings (NYSE-DNA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

132.4 M

Current operating scale indicator.

Revenue Forecast

82.9 M

Forward revenue estimate.

EBITDA

-261.6 M

Current operating profitability reference.

EBITDA Forecast

-140 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Ginkgo Bioworks Holdings (NYSE-DNA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Ginkgo Bioworks Holdings (NYSE-DNA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

1

Weak quality score that deserves closer review.

Beneish M-Score

-3.43

No elevated caution signal from this screen.

Altman Z-Score

-9.3

Lower score that deserves closer risk review.

FCF / Net Income

56.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Ginkgo Bioworks Holdings (NYSE-DNA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Ginkgo Bioworks Holdings (NYSE-DNA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 16, 2026

Days to Earnings

55

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Ginkgo Bioworks Holdings (NYSE-DNA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Ginkgo Bioworks Holdings (NYSE-DNA) Stock Forecast & Technical Outlook

Review Ginkgo Bioworks Holdings (NYSE-DNA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Ginkgo Bioworks Holdings (NYSE-DNA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Ginkgo Bioworks Holdings (NYSE-DNA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Ginkgo Bioworks Holdings (NYSE-DNA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Ginkgo Bioworks Holdings (NYSE-DNA) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Ginkgo Bioworks Holdings (NYSE-DNA) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Ginkgo Bioworks Holdings (NYSE-DNA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Sell

Based on the available recommendation mix, Ginkgo Bioworks Holdings (NYSE-DNA) has a Sell consensus, with 0 buy, 1 hold and 1 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 1
FAQ Fast Investor Answers

Ginkgo Bioworks Holdings (NYSE-DNA) Stock FAQ

Data-supported answers about Ginkgo Bioworks Holdings (NYSE-DNA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$10.73
Estimated upside 14.5%
Valuation Rating
Undervalued
Estimated upside of 14.5%
Analyst Target
$7
Implied downside 25.3%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Ginkgo Bioworks Holdings (NYSE-DNA) is $10.73. This implies an estimated upside of 14.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 14.5% versus the current market price.

The available analyst price target for Ginkgo Bioworks Holdings (NYSE-DNA) is $7. The analyst target implies estimated downside of 25.3%.

The current financial health read for Ginkgo Bioworks Holdings (NYSE-DNA) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Ginkgo Bioworks Holdings (NYSE-DNA) is November 16, 2026.

The latest available data indicates no current dividend yield for Ginkgo Bioworks Holdings (NYSE-DNA).

The current market capitalization listed for Ginkgo Bioworks Holdings is 631 M.

The current enterprise value listed for Ginkgo Bioworks Holdings is 616.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Ginkgo Bioworks Holdings is NYSE-DNA, and the stock is listed on NYSE.

Ginkgo Bioworks Holdings (NYSE-DNA) is listed on NYSE.

The current debt-to-total-capital ratio listed for Ginkgo Bioworks Holdings is 42.9%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Ginkgo Bioworks Holdings is 74.1%. Free float helps investors understand how much of the share base is available for public trading.